3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
113
Lymphoma
101
Leukemia, Myeloid, Acute
94
Myelodysplastic Syndromes
88
Lymphoma, Non-Hodgkin
87
Leukemia
86
Hodgkin Disease
75
Leukemia, Lymphocytic, Chronic, B-Cell
70
Multiple Myeloma
57
Lymphoma, Large B-Cell, Diffuse
57
Lymphoma, Follicular
52
Lymphoma, Mantle-Cell
48
Burkitt Lymphoma
47
Lymphoma, B-Cell, Marginal Zone
45
Leukemia, Myeloid, Chronic-Phase
45
Lymphoma, Large-Cell, Immunoblastic
44
Leukemia, Myeloid, Accelerated Phase
43
Myeloproliferative Disorders
42
Congenital Abnormalities
42
Leukemia, Myelomonocytic, Chronic
40
Neoplasms, Plasma Cell
39
Blast Crisis
38
Recurrence
32
Dendritic Cell Sarcoma, Interdigitating
32
Primary Myelofibrosis
29
Anemia, Refractory, with Excess of Blasts
29
Myelodysplastic-Myeloproliferative Diseases
26
Lymphoma, T-Cell, Cutaneous
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
24
Interventions
fludarabine phosphate
2
Cyclophosphamide
2
AP 1903 reagent
2
fludarabine
1
Whole-Body Irradiation
1
Peripheral Blood Stem Cell Transplantation
1
Mesna
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thalassemia
×
Busulfan
×
Lymphoid
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts